menu
    • menu
    [{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clinic \/ Solid Biosciences"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mayo Clinic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Tetherex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Single-Cycle Adenovirus Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mayo Clinic \/ Tetherex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Tetherex Pharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Ipilimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Mayo Clinic \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"NaNotics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mayo Clinic \/ NaNotics","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clinic \/ NaNotics"}]

    Find Clinical Drug Pipeline Developments & Deals by Mayo Clinic

    Menu

    Mayo Clinic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Solid Biosciences, Mayo Clinic Collaborate on Cardiac Gene Therapy Innovation

                            Details : Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy platform and multiple next-generation cardiac gene therapy programs.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : NaNotics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NaNotics to Collaborate with Mayo Clinic on Nanomedicine Cancer Treatment

                            Details : As part of the collaboration, NaNotics will provide its core nano-depletion platform and Mayo Clinic will provide an antibody of its own design against PD-L1, which will be specific to sPD-L1 once incorporated into a NaNot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 01, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : NaNotics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sorrento Join Hands with Mayo Clinic and Gets FDA Clearance for First Phase 1b Pilot Study Using Sofusa Lympha...

                            Details : Sofusa Lymphatic Drug Delivery System will be used conduct human clinical studies. First study resulting in this agreement is a Phase 1b study of the administration of Ipilimumab Intra-Lymphatically using the Sofusa® DoseConnect™ in Metastatic Melanom...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            November 06, 2021

                            Lead Product(s) : Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Single-Cycle Adenovirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Tetherex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tetherex Pharmaceuticals Ink Licensing Deal with Mayo Clinic for Development of a Novel Single-Cycle Adenoviru...

                            Details : The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19. The Phase 1 open label study, designed to assess safety, reactogenicity and immunogenicity of the single-cycle...

                            Product Name : SC-Ad6-1

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 07, 2021

                            Lead Product(s) : Single-Cycle Adenovirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Tetherex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US Study finds Convalescent Plasma Safe for Covid-19 Patients

                            Details : The findings are based on analysis of safety data from the initial 5,000 hospitalised patients transfused with convalescent plasma under the US Food and Drug Administration (FDA)’s Expanded Access Program (EAP) for Covid-19.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 15, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth